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Abstract. The current mainstay treatment of Parkinson’s disease (PD) consists of dopamine replacement therapy which, in
addition to causing several side effects, does not delay disease progression. The field of gene therapy offers a potential means
to improve current therapy. The present review gives an update of the present status of gene therapy for PD. Both non-disease
and disease modifying transgenes have been tested for PD gene therapy in animal and human studies. Non-disease modifying
treatments targeting dopamine or GABA synthesis have been successful and promising at improving PD symptomatology
in randomized clinical studies, but substantial testing remains before these can be implemented in the standard clinical
treatment repertoire. As for disease modifying targets that theoretically offer the possibility of slowing the progression of
disease, several neurotrophic factors show encouraging results in preclinical models (e.g., neurturin, GDNF, BDNF, CDNF,
VEGF-A). However, so far, clinical trials have only tested neurturin, and, unfortunately, no trial has been able to meet its
primary endpoint. Future clinical trials with neurotrophic factors clearly deserve to be conducted, considering the still enticing
goal of actually slowing the disease process of PD. As alternative types of gene therapy, opto- and chemogenetics might also
find future use in PD treatment and novel genome-editing technology could also potentially be applied as individualized gene
therapy for genetic types of PD.
Keywords: Gene therapy, Parkinson’s disease targets, dopamine, GAD, neurotrophic factors, NRTN, CDNF, MANF, BDNF,
GDNF, optogenetics, chemogenetics, genome editing
INTRODUCTION
Parkinson’s disease (PD) is the second most com-
mon neurodegenerative disease and is estimated to
afflict up to 5.8 million people worldwide [1], with
the increased mean age of the population in the West-
ern world, the prevalence of the disease is projected
to rise. PD is characterized by a slow asymmetric
debut of motor symptoms in the form of muscle rigid-
ity, impaired gait, hypokinesia and tremor as well
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as several non-motor symptoms, including disturbed
emotions, cognition, sleep pattern, and autonomous
dysfunction [2].
The underlying pathophysiology consists of the
cellular accumulation of synuclein- (SNCA), aggre-
gating in insoluble constructs leading to cellular
dysfunction and toxicity [3]. This is especially appar-
ent with the loss of dopaminergic neurons (DA) in the
substantia nigra pars compacta (SNc), disrupting the
many pathways relying on the dopaminergic tonus
arising from this neuron population. The imbalance
leads to aberrant signaling in the circuits of the striatal
projections, giving rise to the parkinsonian pheno-
type [2, 4]. Aggregation of SNCA is also a pathologic
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hallmark of a group of other brain diseases such as
lewy body dementia [5] and multiple system atrophy
[6]. This review will focus on gene therapy for PD, but
as many of the proposed therapies do not necessarily
specifically target PD, it is likely that they could also
prove feasible for treating other -synucleinopathies.
Current treatment regimens for PD mainly involve
administration of levo-dopa (L-DOPA), dopamine
agonists or MAO-B inhibitors or surgery in the form
of deep brain stimulation (DBS) or neuroablative
surgery [7, 8]. However, these treatments are symp-
tomatic and do not prevent PD progression and may
be associated with significant side effects. Thus, the
exploration of novel treatment avenues is clearly
warranted [9].
Gene therapy was first described in 1972 as a means
to “replace bad DNA with good DNA” [10]. The basic
principle still stands but has evolved to become some-
what more sophisticated. Gene therapy can be used to
treat diseases by the introduction of therapeutic genes
or by replacing, silencing, or correcting faulty genes.
Many different approaches exist, but the primary
strategy is the use of engineered non-replicating viral
vectors; predominantly various serotypes of recom-
binant adeno-associated virus (AAV) or lentivirus
[11]. Several studies using viral vectors have provided
evidence for both safety and high fidelity of gene
expression [12–15]. Novel methods of gene delivery
are currently being developed and have been success-
fully utilized in murine models of PD [16, 17]. In
more recent years, gene therapy has also been tested
in several human clinical trials as reviewed below.
With the approval of AAV vectors for gene ther-
apy in Europe and recently in the US [18, 19], it is
expected that the gene therapeutic approach will gain
further ground in the coming years. This review will
present an up-to-date overview of in vivogene therapy
for PD.
So far, several possible targets for genetic treat-
ment of PD have been identified. These targets
can be classified as either disease modifying or
non-disease modifying. The non-disease modifying
treatments are aimed at ailing parkinsonistic symp-
toms by attempting to normalize aberrant firing in
the basal ganglia by expression of either dopamin-
ergic or GABAgenic enzymes. These treatments are
symptomatic and do not alter the underlying patho-
physiological process.
Disease modifying strategies revolve around
stopping PD-mediated cell death and/or regenerat-
ing lost neurons. The most investigated approach has
been nigral overexpression of growth factors found
to have neuroprotective properties (see Tables 4 and
5) [20]. Other possible targets encompass genomic
repair of faulty genes [21], giving rise to toxic SNCA
constructs.
NON-DISEASE MODIFYING TARGETS
The enzyme aromatic acid decarboxylase (AADC)
is part of the dopamine synthetic apparatus (Fig. 1)
and is responsible for the conversion of L-DOPA
to dopamine [22]. The primary clinical approach
towards treatment of PD is the use of L-DOPA, a
precursor of dopamine able to cross the blood-brain
barrier, thus enabling oral treatment. L-DOPA is a
symptomatic treatment unable to halt disease pro-
gression and is associated with several side effects,
including so-called OFF-states. OFF-states are peri-
ods of immobility and incapacity often accompanied
by depression or hypomania, due to erratic func-
tion of the drug. These periods have been attributed
to unpredictable gastric emptying, overload of the
blood-brain barrier carrier system responsible for
transporting L-DOPA as well as insufficient aro-
matic L-amino acid decarboxylase (AADC) levels
Fig. 1. L-tyrosine is converted to L-dihydroxyphenylalanine
(L-DOPA) by tyrosine hydroxylase (TH) using the co-factor
tetrahydrobiopterin, under the rate limit of GTP cyclohydroxy-
lase 1 (GCH1). L-DOPA is further converted into dopamine by
alpha-amino acid decarboxylase (AADC). The three enzymes in
red are encoded by Prosavin gene therapy. PTPS: pyruvoyltetrahy-
dropterin synthase; SPR: sepiapterin reductase.
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[23–26]. The absorption issues have largely been
overcome using new formulations of L-DOPA and
various pump systems.
Several rodent studies found striatal vector-
mediated AADC overexpression to be well tolerated
and able to improve parkinsonian symptoms [27–29].
Further studies in non-human primates (NHP)
[30–33] described a decreased need for medication,
as well as improved motor function off medi-
cation, once a certain level of transfection was
achieved (see Table 1) [31]. The promising results
in NHPs led to the first phase 1 clinical trial
with bilateral AAV2-induced AADC expression in
the putamen of severely affected PD patients pub-
lished in 2008 [14]. The authors found a modest
improvement in the unified Parkinson’s disease rating
scale (UPDRS) and, importantly, found no adverse
effects of AAV-mediated AADC overexpression in
humans. Furthermore, phase 1 trials (see Table 1)
reached the same conclusions regarding improved
symptomatology in the patients while in OFF-state
as well as a general reduction in UPDRS and a
trend towards lower need for L-DOPA [12, 25]. A
follow-up study on patients from a phase 1 study by
Christine et al. [12] showed a discrete increase in
UPDRS scores as well as a minor reduction in activ-
ity of the AADC ligand 18Fluoro-L-m-tyrosine. Both
were, however, still well above baseline. The authors
attribute the decline to ongoing degeneration of non-
transfected still-functioning nigral neurons, implying
AAV-therapy to be permanent with no decline in
expression of transfected cells. There are currently
two ongoing and one planned open label study aimed
at examining the safety profile of AADC therapy,
optimizing dosage and delivery method [34, 35].
These studies will hopefully pave the way for future
randomized placebo-controlled trials.
Should the AADC therapy appear efficient, it is
not suited as a stand-alone treatment due to the
continued need for exogenous L-DOPA. However,
Table 1
NHP trials and clinical trials utilizing AADC
Author Method Subjects Results Reference
Bankiewicz et al.
(2000)
Bilateral convection enhanced
delivery AAV induced AADC
expression in nu. caudatus,
putamen and globus pallidus.
MPTP-treated rhesus
monkeys (n = 4).
Higher increase in gene expression
using CED than conventional
injection. Strong AADC
expression in striatum.
[33]
Daadi et al. (2006) Bilateral convection enhanced
delivery AAV induced AADC
expression in nu. caudatus,
putamen and globus pallidus.
MPTP-treated
macaque monkeys
(n = 4).
Verification of strong striatal AADC
expression after 3 years.
[32]
Forsayeth et al.
(2006)
Dose ranging study with bilateral
putaminal injection of
AAV2-AADC in escalating doses.
MPTP-treated
macaque monkeys
(n = 12).
A minimum dose is needed to
increase L-DOPA response and
FMT-activity in striatum.
[31]
Bankiewicz et al.
(2006)
Unilateral AAV-2 induced AADC
expression in striatum.
MPTP-lesioned
macaque monkeys
(n = 8).
PET-verified increase in AADC
activity after 2 years. Consistently
higher L-DOPA sensitivity in
treatment group.
[30]
Eberling et al.
(2008)
Open label study. Bilateral
AAV2-induced AADC expression
in putamen.
Severely affected PD
patients (n = 5).
Modest improvement of OFF-state
UPDRS-score. 30% increase in
putaminal FMT activity at 6-month
follow-up.
[14]
Christine et al.
(2009)
Open label study. Bilateral
AAV2-induced AADC expression
in putamen. High and low dosage.
Moderately affected
PD patients (n = 10).
Improvement of UPDRS scores.
Longer time in ON-state. Therapy
well tolerated. High dose with
higher FMT-activity than low dose
at 6-month follow-up.
[12]
Hadaczek et al.
(2010)
8-year follow up on the study by
Bankiewicz et al. (2006).
MPTP-lesioned
macaque monkeys
(n = 2).
No decrease in FMT signal and
continued robust AADC
expression.
[183]
Muramatsu et al.
(2010)
Open label study. Bilateral
AAV2-induced AADC expression
in putamen.
Moderately to severe
affected PD patients
(n = 6).
Decrease in UPDRS scores by 46%
in OFF-state. At 6-month
follow-up. Persistent FMT activity
at 24 weeks.
[25]
Mittermeyer et al.
(2012)
4-year follow-up on Christine et al.
(2009).
Moderately affected
PD patients.
Discrete decline in AADC activity at
4-year follow-up. Slight increase in
UPDRS-score.
[24]
Clinical and preclinical studies with AADC-gene therapy. FMT, 18Fluoro-L-m-tyrosine, a tracer specific for AADC.
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as the patients in all the clinical trials have reported
improved L-DOPA response as well as a general
improvement of UPDRS scores, it is possible that
AADC gene therapy can be included in future treat-
ment aimed at ameliorating otherwise incontrollable
motor fluctuations and be used on par with DBS in
PD therapy.
AADC, TH, and GCH
An enticing approach to symptomatic treat-
ment of PD, is to completely reconstruct the
dopamine synthesis apparatus by introducing all the
genes responsible for the conversion of tyrosine to
dopamine (Fig. 1) in cells of the target area. This
requires the enzyme tyrosine hydroxylase (TH) along
with the co-factor tetrahydrobiopterin (BH4) for con-
verting the amino acid L-tyrosine into L-DOPA
which in turn is converted into dopamine by AADC.
The rate limiting step for the synthesis of BH4 is
the enzyme GTP cyclohydroxylase 1 (GCH) [36]. By
expressing the three enzymes (TH, GCH and AADC)
in the striatum, it should be theoretically possible
to reduce, if not eliminate, the need for exogenous
L-DOPA, which could ensure a stable dopamine
tonus eliminating wearing off effects and off-target
effects.
An early study by Kaplitt et al. (1994) reported
behavioral recovery in 6-OHDA treated rats subjected
to AAV-TH in the striatum [37]. This approach was
investigated in an NHP study by During et al. (1998),
who injected a mix of AAV-TH and AAV-AADC
in the striatum of green monkeys [38]. They were,
however, unable to detect any behavioral effect of the
treatment compared to controls injected with empty
vector. Nevertheless, they could detect an increased
dopamine production in the striatum. The lack of clin-
ical effect in their study could possibly be due to a
subclinical restoration of dopamine levels because of
the low amounts of vector injected [38] or lack of
BH4.
Later, most research on reconstitution of the
dopaminergic apparatus has focused on expressing
all three dopaminergic enzymes. However, the deliv-
ery of all three genes represents a hurdle, as the three
enzymes combined are too big to fit into a single
AAV genome. This challenge has been met in two
ways. Either by injecting a mixture of three differ-
ent AAV-vectors, each containing one of the desired
transgenes, or by using LV, which has a higher trans-
gene expression capacity. Rodent studies indicate
that both methods are well tolerated and efficient at
reducing the parkinsonian phenotype in PD models
[39–47].
The success prompted further investigation in
NHPs (see Table 2) with both the tricistronic and
lentiviral approach. An early study utilizing the
tricistronic vectors showed overexpression of TH,
AADC and GCH [48] to be both possible and well
tolerated. Bearing in mind the lack of clinical effect
seen in the study by During et al. (1998), Mura-
matsu and colleagues (2010) injected an increased
titer and added AAV2-GCH to the injections and
presented a significant increase in dopamine produc-
tion as well as a robust rescue of the parkinsonian
phenotype in MPTP-treated marmosets [48], with
Table 2
NHP trials and clinical trials combining TH and AADC
Author Method Subjects Results Reference
During et al.
(1998)
Treatment with mix of AAV-TH
and AAV-AADC in the
striatum.
MPTP-treated green
monkeys (n = 12).
Biochemically measured increase
of dopamine production. No
behavioral difference from
non-transfected individuals.
[38]
Muramatsu et al.
(2002)
Unilateral AAV induced
expression of TH, GCH and
AADC in the striatum.
MPTP-treated marmosets
(n = 4).
Bilateral improvement of motor
skills; improved fine motor
skills.
[48]
Sehara et al.
(2017)
Follow-up on Muramatsu et al.
(2002).
MPTP-treated marmoset
(n = 1).
Continuous effect on motor
skills. Persistent expression of
transfected genes.
[49]
Jarraya et al.
(2009)
LV-induced bilateral putaminal
expression of TH, GCH and
AADC.
MPTP-treated macaques
(n = 26).
Correction of motor deficits at 44
months. No observed
dyskinesias.
[50]
Palfi et al.
(2014)
Open label study. LV-induced
putaminal expression of TH,
GCH and AADC.
Patients with advanced
bilateral PD (n = 15).
Therapy is deemed safe and
tolerable. Improved UDPRS
scores and lower need for
medication.
[51]
Clinical and preclinical studies with combined TH-, AADC- and GCH-gene therapy.
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the effect persisting at 15 year follow-up in one
monkey [49].
It has been proposed that the packaging of all genes
within one vector ensures joint expression of the pro-
teins and thus excludes the hassle of a tricistronic
system. The LV approach was shown to be efficient
in rats [39]. Prompting a study on the effects of a
LV vector expressing AADC, TH and GCH in the
putamen of MPTP-treated macaque monkeys. The
therapy was well tolerated, and the subjects showed
marked improvement of parkinsonian symptoms with
no signs of dyskinesias. Microdialysis showed an
approximately 50% restoration of normal dopamine
tonus [50]. A subsequent phase 1 trial examining
the effect of injection of LV-TH-GCH-AADC under
the name of Prosavin to the putamen was spon-
sored by Oxford Biomedica [51]. The authors of the
study found the drug to be well tolerated and able
to reduce UPDRS scores in patients off medication
by 12 points as well as decrease the general need
for medication. The study is ongoing with several
planned follow-up visits to further evaluate long-term
safety and efficacy [52]. The mechanism behind the
apparent effect of Prosavin is not yet fully understood,
but it is theorized, that increased dopamine levels in
the extracellular environment achieved by transfected
cells can normalize firing rates of afferent projec-
tion axons in the same manner as DBS [38, 51, 53].
The only clinical trial on Prosavin, thus advocates
further investigations regarding the vector dosage
before it is deemed feasible to progress to a phase 2
study [51].
Vesicular monoamine transporter 2 (VMAT2) is
a macromolecule which transports dopamine into
intracellular synaptic vesicles of dopaminergic neu-
rons for release into the synaptic cleft [26]. A study
by Sun et al. (2004) compared the effect of injecting
a herpes simplex (HSV) vector containing either TH,
GCH and AADC or TH, GCH, AADC and VMAT2 to
striatal GABAergic neurons in a 6-OHDA-rat model.
The authors hypothesized that adding VMAT2 to the
vector would further stabilize the dopaminergic tonus
by a more stable release of dopamine. They found the
4-gene vector to be superior to the 3-gene vector in
controlling amphetamine-induced rotations as well as
K+-induced dopamine release and increased levels of
striatal dopamine in general [45].
Glutamic acid decarboxylase (GAD)
A significant consequence of decreased striatal
dopaminergic tonus is an increase in excitatory
activity of the circuits leading from the predominantly
glutamatergic subthalamic nucleus (STN). The depo-
larization pattern of the STN is affected in the form
of increased firing frequency (∼30 Hz) along with
spike bursts of activity with subsequent afterhyper-
polarization [54]. The excitatory signal affects the
internal globus pallidus (GPi) and substantia nigra
pars reticulata (SNr). Increased activation of GPi and
SNr exerts inhibitory effect on the thalamocortical
circuits resulting in the classical parkinsonian motor
symptoms [54]. Baron et al. (2002) showed that infu-
sion of the GABAA agonist muscimol into the STN
and GPi in MPTP-treated monkeys resulted in miti-
gation of subthalamic hyperactivity and amelioration
of PD symptomatology [55]. The use of gene ther-
apy in this approach is attractive since the use of
permanently implanted pumps for CNS stimulation
is undesirable due to the risk of infection, catheter-
related issues, etc.
An early study investigating subthalamic GAD
overexpression in a rat model of PD found the ther-
apy to be both well tolerated and able to diminish
parkinsonian motor symptoms [56]. The authors even
found the therapy to exert neuroprotective effect
on nigral neurons. A subsequent rodent study was
unfortunately unable to replicate the neuroprotec-
tive effect, but nevertheless reproduced the improved
motor effects [57].
In a subsequent NHP trial by Emborg et al. [58]
(see Table 3) the effect of unilateral GAD expres-
sion was pronounced and prompted the advance to
human trials. Phase 1 clinical trials funded by the
company Neurologix found no adverse effects related
to the treatment and reported a significant sustained
improvement of UPDRS scores in both ON- and
OFF-state [59, 60]. The latter data should, however,
be interpreted with caution as they originate from
an open label study. The safety profile gave rise to
a phase 2 study by LeWitt et al. (2011) that con-
firmed AAV-GAD to be an efficient treatment for
PD with a significant decrease in UPDRS-score 6
months after transfection as compared to patients sub-
jected to sham surgery [13]. A recently published
follow-up study on this work shows the effect to be
persistent for 12 months regarding both attenuation
of metabolic hyperactivity in the thalamus, striatum,
prefrontal anterior cingulate gyrus and orbitofrontal
cortices as wells as an improved UPDRS-score [61].
Further studies have yet to be undertaken as the fund-
ing company Neurologix no longer exists and, as
such, a scheduled long-term follow-up study and an
additional phase 2 trial have been cancelled. Thus,
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Table 3
NHP trials and clinical trials utilizing GAD
Author Method Subjects Results Reference
Emborg et al.
(2007)
Unilateral AAV-mediated GAD
expression in STN after
MPTP-lesion.
MPTP-treated rhesus monkeys
(n = 13).
Well tolerated. No overall
decrease in morbidity.
Sub-analysis with decreased
bradykinesia −16%, gross
motor skills (–26%) and tremor
(–36%). Unilaterally decreased
FDG-metabolism.
[58]
Kaplitt et al.
(2007)
Open-label study. Unilateral
AAV-mediated GAD
expression in STN.
PD patients. Hoehn Yahr stage
≤3 (n = 12) with substantial
motor fluctuations and age <70.
28% reduced UPDRS score. PET
measured reduction in thalamic
metabolism. Well tolerated
therapy.
[59]
Feigin et al.
(2007)
Open-label study. Unilateral
AAV-mediated GAD
expression in STN.
PD patients in Hoehn Yahr stage
≤3 (n = 12).
FDG and PET verified decline of
glutamatergic hyperactivity
and reduction of aberrant
activity in basal ganglia.
[60]
Lewitt et al.
(2011)
Phase 2 randomized controlled
trial. Bilateral injection of
AAV2-GAD.
PD patients scoring ≥25 on
UPDRS motor score (n = 37).
UPDRS score decreased by 8.1
points in AAV2-GAD group as
compared to 4.7 in sham group
no serious adverse events
related to surgery or treatment.
[13]
Niethammer et al.
(2017)
12-month follow up on LeWitt
et al. (2011).
PD patients scoring ≥25 on
UPDRS motor score (n = 37).
Effect from Lewitt et al. (2011)
persisting
[61]
Clinical and preclinical studies with GAD-gene therapy.
the development of GAD as a possible therapy for
PD has, so far, come to a halt.
DISEASE MODIFYING TARGETS
A substantial amount of research has focused on
growth factors as a treatment target for neurode-
generative diseases, including PD. Particular focus
has been placed on the glial cell-line derived neu-
rotrophic factor family of ligands (GFL) [62] that
encompasses glial cell-line derived neurotrophic fac-
tor (GDNF), neurturin (NRTN), artemin (ARTN) and
persephin (PSPN) [63]. The GFL signals by acti-
vating the RET receptor complex with the GDNF
family receptor  (GFR) as a co-factor, initiating
the MAP kinase and PI3-kinase pathways promoting
neuronal survival and neuritogenesis [64, 65]. Activa-
tion of GFR also activates the transcriptional factors
Nurr1 and Pitx3 which are crucial for the activation of
genes encoding TH, VMAT2, DAT [42] and AADC
[66, 67].
GDNF
Several studies investigating direct GDNF deliv-
ery to the SN and striatum have shown that GDNF
induces neurite sprouting and reduces parkinsonian
behavior in toxin models of PD [62, 68–70]. The latter
was reproduced in phase 1 trials [66, 71], but not
in a subsequent phase 2 trial [11]. The lack of
effect of GDNF infusion has been attributed to
insufficient spread of the drug, potentially due to
pump malfunction, as well as an insufficient num-
ber of residual neurons for GDNF to affect [11].
For this reason, the gene therapeutic approach was
explored. Several animal studies indicated that injec-
tion of AAV-GDNF in the putamen is both safe
and efficient at treating parkinsonian behavior in
murine PD models [72–75]. As alternative to viral
vector delivery, a recent study by Espadas-Alvarez
et al. (2017) achieved GDNF overexpression in
dopaminergic cells using a novel transfection method
called neurotensin-polyplex, utilizing the neurotensin
receptor for introducing nanoparticles containing
plasmids for expression of GDNF in dopaminer-
gic cells under control of the tetracycline response
element and reverse tetracycline-controlled transac-
tivator. This method enables controlled expression
of GDNF by supplying tetracycline, rendering oth-
erwise constant expression controllable due to the
need for exogenous stimulation [76]. Another new
approach to the delivery of GDNF gene therapy
was reported by Yurek et al. (2017) who delivered
nanoparticles consisting of a 30-mer lysine polymer
and a plasmid encoding GDNF to the midbrain of rats
[77]. They showed that subsequent treatment with 6-
OHDA increased the number of surviving TH+-cells
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and also improved rotational behavior in a cylinder
test [77].
The anti-parkinsonistic effect of viral vector-
mediated GDNF overexpression in dopaminergic
midbrain neurons was also tested in aged and MPTP-
treated monkeys with promising results [78–81] (see
Table 4). Among the NHP studies, one study raised
significant safety concern, as parkinsonian rhesus
Table 4
NHP trials and clinical trials utilizing GDNF
Author Method Subjects Results Reference
Kordower et al.
(2000a)
Unilateral injection of LV-GDNF
into the caudate nucleus,
putamen and SN.
Aged non-lesioned macaques
approx. 25-years-old (n = 8).
Robust antero- and retrograde
distribution of GDNF-vector.
Strong trend towards unilateral
improved 18 F-DOPA uptake.
85% increase in TH-positive
neurons on treated side.
[184]
Kordower et al.
(2000b)
Unilateral MRI-guided injection
of LV-GDNF in either
putamen, SN or caudate
nucleus after MPTP lesion.
Unilaterally MPTP-treated young
macaques (n = 12).
44% increase in
TH-immunoreactive cells in
striatum compared to controls.
>300% increase in FD-uptake
in left striatum. Rescue of
motor behavior in all groups.
[184]
Kozlowski et al.
(2001)
Bilateral injection of AAV-GDNF
vector in caudate nucleus.
Euthanasia 1 week after
operation.
St. Kitts green monkeys (n = 4). First proof, that humane GDNF
can be expressed in primates
utilizing an AAV-vector.
Increased GDNF amount in
striatum.
[185]
Palfi et al. (2002a) Unilateral injection of LV-GDNF
into the caudate nucleus,
putamen and SN.
Macaques aged between 24 to 27
years (n = 4).
Unilateral >800% increase in
TH-positive cells in striatum.
[186]
Palfi et al. (2002b) Unilateral injection of LV-GDNF
into the caudate nucleus,
putamen and SN 1 week after
MPTP-lesion.
Unilaterally MPTP lesioned
Rhesus monkeys (n = 8).
Overall GDNF-mediated increase
in TH-positive cells in striatum
by >700%.
[186]
Eslamboli et al.
(2005)
Unilateral injection of
AAV2-GDNF in the striatum
and SN 4 weeks prior to
6-OHDA lesion.
Marmoset monkeys (n = 11) with
unilateral 6-OHDA mediated
nigral forebrain bundle lesion.
19% survival of nigral
dopaminergic cells. Uncertain
mitigation of parkinsonian
behavior.
[78]
Eberling et al.
(2009)
Unilateral injection of
AAV2-GDNF in putamen after
MPTP-lesioning.
Unilateral MPTP-lesion Rhesus
monkeys.
Bilaterally increased striatal
metabolism. 60 ± 6% decrease
in CRS scores.
[81]
Su et al. (2009a) Bilateral CED of AAV2-GDNF
in either putamen with high- or
low titer or to SN.
Macaques aged >20 years
(n = 17).
No detectable immunological
response to therapy after 6
months. SN group showed
significant weight loss
(–19.4%) not attributable to
therapy.
[82]
Su et al. (2009b) Bilateral CED of AAV2-GDNF
in putamen 4 months after
MPTP-lesion.
Unilaterally MPTP-treated
macaques (n = 11).
No detectable immunological
response. Bilaterally enlarged
TH+ fibers in striatum.
[82]
Kells et al. (2010) Bilateral AAV2-GDNF delivery
to putamen after lesion.
Unilaterally MPTP-treated
macaques (n = 15).
Robust improvement of motor
behavior at 24 months. Effect
proportional with severity of
lesion. 3-fold increase in
striatal dopamine.
[80]
Emborg et al.
(2014)
Unilateral MRI-guided
convection enhanced delivery
of either low titer or high titer
AAV5-GDNF vector to
putamen.
Macaque monkeys (n = 4). Higher GDNF expression with
higher dose in both SN and
striatum.
[187]
Preclinical studies with GDNF-gene therapy. CRS: Clinical rating scale consisting of 14 parkinsonian features consisting of tremor, locomo-
tion, freezing, fine motor skills, bradykinesia, hypokinesia, balance, posture, startle response, gross motor skills. Evaluated bilaterally where
applicable and given a score from 0–3 with 0 being the best. Severe parkinsonism being viewed as a score >20. CED: Convection enhanced
delivery.
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monkeys injected bilaterally in the SN with AAV-
GDNF showed no motor improvement, but instead
presented a significant weight loss [82]. However,
based on convincing data from other studies deliver-
ing NRTN, the sibling of GDNF, to the SN [83–85],
the FDA has approved an American phase 1 trial cur-
rently recruiting advanced PD patients for an open
label safety, dosage elevation study, examining the
effect of bilateral delivery of an AAV2-GDNF vector
to the putamen with a 12-month follow-up [86].
NRTN
NRTN has been the subject of a great deal of
attention as it has been also been found to exert pro-
tective effect on dopaminergic midbrain neurons [62].
NRTN roughly use the same pathways as GDNF, both
activating Nurr-1. While GDNF mainly acts through
the co-receptor GFR1, NRTN has been found to
rely on the co-receptor GFR2 [87]. NRTN has been
shown to improve motor behavior in both rodents
[88–90] and NHPs [83, 91, 92] (see Table 5). Like
the animal experiments with GDNF, NRTN seemed to
be good news for PD patients. Especially after a suc-
cessful phase 1 trial, testing bilateral AAV2-NRTN
infusion into the putamen, sponsored by the company
Ceregene [93] (see Table 5). A subsequent phase 2
trial [9] with the same approach was sadly unable
to meet its primary endpoint, as there was no signifi-
cant difference in motor scores in the treatment group
compared to controls at 12-month follow-up. Some
secondary endpoints were, however, met as there was
a significant improvement in self-reported activities
of daily living (ADL) and a minor but significant
improvement in motor scores at 18-month follow-
up. These findings could point towards a delayed
effect of AAV2-NRTN. However, the improvement
in motor scores at 18-months was observed with-
out blinding of the patients, and consequently the
risk of observer bias means that the results should
Table 5
NHP trials and clinical trials utilizing NRTN
Author Method Subjects Results Reference
Kordower
et al. (2006)
Unilateral infusion of AAV2-NRTN
into the striatum, caudate nucleus
and SN, 4 days after MTPT lesion.
Unilaterally MPTP-treated
macaques (n = 20).
Therapy well tolerated. 88%
reduction in CRS score. Antero-
and retrograde transport of vector
found. Preservation of nigral
neurons and striatal terminals after
10 months.
[91]
Herzog et al.
(2007)
Unilateral injection of AAV2-NRTN
into the caudate nucleus and
putamen.
Macaques aged >20 years
(n = 3).
Well tolerated therapy at 8 months.
∼20% Increased striatal
metabolism. Increased number of
TH+ cells in striatum.
[92]
Herzog et al.
(2008)
Bilateral injection of AAV2-NRTN in
the caudate nucleus and putamen
in high, medium and low dose.
Naive cynomolgus monkeys
(n = 12).
No observed adverse effects.
60–65% increase in striatal TH+
density. No difference between
high and medium titer. No increase
in nigral TH+ at 3 months.
[83]
Marks et al.
(2008)
Open label study. Bilateral
intraputaminal injections of either
high or low dose AAV2-NRTN.
PD-patients in Hoehn-Yahr
stage 3-4 aged between
35–70 years.
No serious adverse events at 1 year.
36% improvement of UPDRS
OFF-state motor scores. No change
in striatal 18F-L-DOPA uptake
from baseline.
[93]
Marks et al.
(2010)
Double blind sham-surgery
controlled randomized trial.
Bilateral putaminal injection of
AAV2-NRTN.
PD-patients aged 35–75 years
scoring >30 in the motor
part of UPDRS in
OFF-state averaging at 3.03
in Hoehn Yahr scale
(n = 58).
Vector not superior to sham surgery
at 12 months. 6 subjects developed
antibodies against vector. Several
secondary endpoints met.
Subpopulation with improved
motor score at 18-months.
[9]
Bartus et al.
(2013)
Open label study. Bilateral injection
of AAV2-NRTN to SN, and either
low- or high dose injection in
putamen.
PD-patients in Hoehn-Yahr
stage 3-4 aged between
35–70 years (n = 12).
No serious adverse events at 2-year
follow-up. Approximately 5-point
decrease in UPDRS-motor-score in
OFF-periods. No change in ADL.
[85]
Warren
Olanow
et al. (2015)
Randomized double blinded
sham-surgery controlled study.
Bilateral injection of AAV2-NRTN
into SN and putamen.
PD-patients in Hoehn-Yahr
stage 3-4 aged between
35–70 years (n = 51).
Therapy did not prove superior to
sham surgery in improving motor
score at 15-24-month follow-up.
Therapy well tolerated.
[84]
Clinical and preclinical studies with NRTN-gene therapy. UPDRS, United Parkinson Disease Rating Scale; ADL, Activities of daily living.
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be interpreted with caution (see Table 5). Nonethe-
less, post-mortem studies of six subjects from clinical
trials testing AAV2-NRTN delivery to putamen per-
formed by Bartus et al. [94, 95] appeared to show
that longer exposure to NRTN was associated with a
small increased number of TH-positive cells.
The failure of the AAV2-NRTN study to meet its
primary endpoint might be due to poor transfection
rate or potentially poor retrograde transport in nigral
dopamine neurons after putamen administration of
the vector. For this reason, Bartus et al. (2011) tested
intranigral delivery of AAV2-NRTN in rodents and
monkeys and found it to be both feasible and safe
[96] (see Table 5), despite earlier findings that it might
produce unwanted weight loss in rodents [82]. Subse-
quently, in a clinical trial, AAV2-NRTN delivery into
the SN in addition to putamen and higher vector titers
were found to be well tolerated and reduced UPDRS
scores in the treated subjects [85]. The ensuing ran-
domized phase 2 trial utilizing the same approach [84]
(see Table 5), with a 15-24-month follow-up, sadly
also failed to meet its primary endpoint, as AAV2-
NRTN was not found to be superior at improving
motor scores compared to sham surgery. The NRTN
in the form used in previously mentioned studies has
high binding affinity for extracellular heparin which
may lead to decreased tissue diffusion [97]. Therefore
Runeberg-Roos et al. (2016) has tested a new isoform
of NRTN with lower affinity for heparin in rodent
brains that should enable further diffusion distances
and deserves further attention [97].
A potential explanation why positive results from
phase 1 studies have been hard to confirm in phase 2
trials could be that the apparent clinical benefit from
GDNF and NRTN in open-label trials could be due to
placebo effects in PD-patients [98]. Another point of
criticism is that the clear effect of GFLs in 6-OHDA
and MPTP animal models may not be valid at evalu-
ating growth factors, as these animal models do not
adequately mirror the underlying pathophysiology of
PD [99]. Many of the animal studies cited in this
manuscript rely on retrograde transport of gene ther-
apeutic vectors expressed in SN after injection into
the striatum. It has, however, been shown by Venda
et al. (2010) that SNCA reduces intracellular trans-
port through impairment of the Golgi apparatus [100].
The same transport impairment has been found in
human post-mortem studies [94, 95]. This implies
that it might be a good idea to test different injec-
tion sites when testing antiparkinsonian vectors. In a
study by Decressac et al. (2011) investigating GDNF
expression in a SNCA-expressing model of PD, there
was no beneficial effect of GDNF on PD behavior in
mice [101]. Consequently, Decressac et al. proposed
that the reason for failure in the randomized human
trials might be due to the presence of SNCA impair-
ing expression of Nurr1, which blocks the pathway
facilitating the neuroprotective function of the GFL.
This appears to speak against the proposed idea of
neuroprotection through expression of GFL alone.
However, caution may be warranted since the SNCA-
expressing mouse model used in this study appears
to express SNCA at a far greater level than that in PD
and other -synucleinopathies [102].
Nurr1
Nurr1 is an intranuclear receptor found to play
a significant role in the development of dopaminer-
gic neurons and transcriptional regulation of AADC,
TH, DAT and VMAT2 [103]. Increased levels of
SNCA impairs Nurr1 function [104], thus hamper-
ing the effect of GDNF and other members of GFL.
In a paper from 2015, Oh et al. examined the effect
of AAV-mediated overexpression of Nurr1 and its
co-transcription factor Foxa2 in the midbrain of a
MPTP-mouse model [105]. They could rescue 69%
of the neurons ipsilateral to the injection site, includ-
ing a large amount of striatal fibers, as well as detect
a decrease of the proinflammatory cytokines IL-1
and iNOS. The neuroprotective effect was also found
in behavioral studies with bilateral overexpression
of Nurr1 and Foxa2 [105]. Further studies overex-
pressing Nurr1 is warranted before any conclusions
can be made, but the perspectives are intriguing,
as overexpression alone is neuroprotective. Also, by
expressing Nurr1 and Foxa2 in conjunction with
GDNF or NRTN it is possible that the GFL may still
prove to be efficient PD therapy [106].
Cerebral dopamine neurotrophic factor (CDNF)
and mesencephalic astrocyte-derived neural
factor (MANF)
CDNF and MANF constitute a family of neural
growth factors not related to GFL. The CDNF/MANF
family has been found to exhibit a neurotrophic effect
on nigral dopaminergic neurons through a hitherto
unknown mechanism [20]. The factors are found in
both in the extracellular environment in response
to ischemia and status epilepticus as well as in the
endoplasmatic reticulum (ER) where they reduce ER
stress by modulating the unfolded protein response
[107–109].
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The unfolded protein response is an intracellular
response to accumulation of misfolded proteins and
works through halting protein translation, increas-
ing molecular chaperone production, and increasing
protein degradation [107, 110]. The CDNF/MANF
family’s mode of action could prove to be an inter-
esting take on PD modulation, given the role of
ER stress in neurodegenerative diseases [111]. The
CDNF/MANF family is a relatively new discovery
with MANF first described by Petrova et al. (2003)
[112] and CDNF by Lindholm et al. (2007) [113].
MANF was shown by Petrova et al. [112] to pro-
mote survival of dopaminergic neurons in vitro and
has later been shown to be on par with GDNF at
protecting and restoring dopaminergic neurons and
motor behavior in a 6-OHDA rat model with injec-
tion directly into the striatum [113]. To date, three
studies have used gene therapy to overexpress CDNF
in 6-OHDA based rodent models. One study made
use of an AAV2-vector to deliver the gene encod-
ing CDNF to the striatum in a rat model. Subsequent
medial forebrain bundle lesion with 6-OHDA showed
a significantly improved amphetamine-induced rota-
tion test, but only partial protection of TH+ fibers and
neurons [114]. Another study examined the effect
of striatal AAV2-CDNF delivery in a rat model, 6
weeks after 6-OHDA treatment and found a signifi-
cant improvement of spontaneous locomotion as well
as decreased amphetamine-induced rotations [115].
It was also possible to detect a significant protection
of TH-expressing cells measured by immunohisto-
chemistry. In addition, a striatal increase in activity
of the DAT-ligand [11C]-2-carbomethoxy-3-(4-
fluorophenyl)-tropane points towards a functional
recovery of the striatum [115]. A third study used
a LV vector to compare the effect of LV-mediated
nigral expression of either CDNF, MANF or a com-
bination of the two in a 6-OHDA rat model [116].
The study was unable to completely reproduce the
impressive results from the former studies. How-
ever, combined overexpression of MANF and CDNF
resulted in decreased amphetamine-induced rotations
as well as an increased number of TH+ cell bodies in
the SN and increased TH+-fiber density in the stria-
tum, suggesting a synergistic effect of the two factors
[116]. A recent study investigated the effect of AAV9-
MANF in the striatum of 6-OHDA-treated rats [117].
They found the protein to be widely expressed with
signs of both antero- and retrograde transport with
no significant inflammatory response as well as sus-
tained MANF expression for 16 weeks. Injection of
AAV9-MANF was able to halt the neurodegeneration
caused by 6-OHDA and appeared to possibly regen-
erate lost nerve terminals [117]. Supported by the
positive results using CDNF, a study in MPTP-treated
monkeys is currently being conducted [20].
Brain-derived neurotrophic factor (BDNF)
BDNF belongs to the neurotrophin family of
growth factors and primarily binds to the receptor
tropomyosin-related kinase B (TrkB) [118]. It has
been found to promote neuron survival and to pro-
tect dopaminergic neurons from toxic insults [119,
120]. BDNF can induce neurogenesis after intraven-
tricular injection in rats and this could potentially
compensate for cell loss in PD [121]. BDNF has
received much of attention as a therapeutic option
in several neurodegenerative diseases [122] and in
relation to neurotraumatology [123]. Native BDNF
has been found to be reduced in the SN of PD
patients [124], and inhibition of nigral BDNF expres-
sion in rats induces parkinsonian symptoms [125].
Relatively few studies have examined gene therapy
utilizing BDNF as a therapeutic option in PD. This
is surprising given the apparent effect of continuous
infusion of a BDNF ligand on parkinsonistic behav-
ior and dopaminergic cell survival in an older monkey
study [126].
A study by Klein et al. (1999) injected an AAV-
vector encoding BDNF in the SNc of rats with a
partial 6-OHDA lesion [127]. The animals treated
with BDNF showed a general increase in locomo-
tor activity and a reduction in amphetamine-induced
rotations, but no signs of neuroprotection. Another
study attempted to compare the effect of BDNF vs.
GDNF in a 6-OHDA rat model and found GDNF
to be superior in terms of both neural protection as
well as at reducing parkinsonian symptoms [128].
In addition, it was impossible to detect a statisti-
cal difference in the behavior of rats treated solely
with HSV1-GDNF and rats treated with a com-
bination of HSV1-GDNF and HSV1-BDNF, thus
suggesting that GDNF is a superior therapeutic
option [128]. Despite the apparent earlier failure of
BDNF as gene therapeutic treatment for PD symp-
toms, BDNF was reinvestigated in a fairly recent
study by Hernandez-Chan et al. (2015) [129]. The
authors utilized the novel gene delivery method
mentioned above called neurotensin-polyplex [17]
to overexpress BDNF in a 6-OHDA rat model of
early parkinsonism. The neurotensin-polyplex is a
non-viral delivery method that utilizes neurotensin
receptors to induce receptor-mediated internalization
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of nano-coated genetic cargo specifically in dopamin-
ergic neurons [17]. The authors proposed that the
scarcity of dopaminergic nerve terminals in the stria-
tum in earlier studies was not sufficient to facilitate
proper retrograde transport of the vector and might
thus not facilitate nigral expression of BDNF at ther-
apeutic amounts. Using a less severe PD model, it was
possible to detect massive neuritogenesis, but no out-
right neurogenesis in both SN and the striatum [129].
In the behavioral tests, it was possible to detect sub-
stantial improvement in parkinsonian behavior [129].
These results point towards a revival of BDNF as a
potential candidate for PD therapy. There is, however,
still a long way to go, as BDNF must be tested in
other models of PD. Also, estimations of potential
long-term effects of elevated BDNF levels should
be considered before BDNF-therapy can advance to
non-human primate studies, as an earlier study raised
safety concerns regarding elevation of striatal BDNF
levels [130]. Thus Lapchak and colleagues (1993)
found that chronic delivery of BDNF to the SN in
healthy rats produced a hypodopaminergic phenotype
with increased rotatory behavior and decreased TH
mRNA on the injected side [130].
Vascular endothelial growth factor (VEGF)
The VEGF family of proteins consists of VEGF-A
VEGF-B, VEGF-C, VEGF-D, and placental growth
factor (PLGF), with VEGF-A, and to some extent
VEGF-B, being the most physiologically active
[131]. The VEGF family has been intensely stud-
ied due to its angiogenic role in tumor growth [132].
However, subsequent research also found the factors
able to exert neurotrophic, potentially neuroprotec-
tive, effects in the CNS [16]. The VEGF family
peptides mainly mediate their effects via the tyrosine
kinase receptor and vascular endothelial growth fac-
tor receptor 2 (VEGFR-2) using the neuropillins NP1
and NP2 as co-receptors [133] with vascular endothe-
lial growth factor receptor 1 (VEGFR-1) acting as a
decoy receptor [134]. Neuroprotective/neuroptrophic
effects have been observed by overexpressing VEGF
in both the striatum [73, 135] and SNPc [16] in 6-
OHDA-treated rodents. These effects are believed
to be mediated by VEGFR-2 activation, leading
to increased angiogenesis with improvement of
microcirculation and through microglial proliferation
causing increased extracellular levels of the antiox-
idant glutathione and increased GDNF secretion
[134]. In addition to the neurotrophic effects, VEGF
has also been found to prevent apoptosis by out-
competing the apoptosis-inducing factor Sema3A for
neuropillin-binding sites [136]. Also, VEGF-A has
been found to activate the anti-apoptotic PI3K/AKT
pathway [137], lending additional credence to fur-
ther investigation of the VEGF family as a future
target for PD treatment. Due to the implication of
VEGF in oncogenesis [132] it is a relevant concern
that overexpression may increase the risk of CNS
cancers. However, gene therapy with VEGF-A has
already been utilized in patients suffering from coro-
nary disease with good results [138], which speaks
for the feasibility of VEGF gene therapy for vascu-
lar diseases. The usage of VEGF as a neuroprotective
factor is complicated by the fact that the effect is dose-
dependent with high levels of VEGF inducing brain
edema [139]. As such the dosage of VEGF should be
carefully studied in animal models before advancing
to human trials.
OTHER TARGETS AND STRATEGIES
In addition to the above-mentioned peptides for
gene therapeutic treatment of PD, several other possi-
ble genes deserve attention as potential targets in PD.
One such target is the neuron restrictive silencing fac-
tor (NRSF), a zinc finger transcription factor found to
be involved in restriction of neuronal factors in non-
neural cells and regulation of neurogenesis [140].
Yu and associates (2013) reported that NRSF knock-
out mice were more susceptible to MPTP-induced
dopaminergic cell death, as lack of NRSF leads to
lower levels of BDNF and TH [140]. It is possible that
by upregulating NRSF in conjunction with BDNF,
it would be possible to enhance the neuroprotective
effects of BDNF. However, sparse data are available
on NRSF in PD, but as the role of long coding RNAs
have been associated with several neurodegenerative
diseases, epigenetic regulation provides a novel inter-
esting avenue of research regarding several diseases
[141].
Neuropeptide Y (NPY) is an abundantly expressed
neuropeptide in the CNS that exerts neuroprotective
effects by acting through the Y2 receptor (Y2R) [142,
143]. Cannizzaro et al. [144] detected increased levels
of NPY mRNA in the basal ganglia of PD patients,
which has been interpreted as a compensatory, yet
unsuccessful neuroprotective mechanism of the basal
ganglia to prevent tissue damage. So far, no studies
have directly tested the effect of gene therapy with
NPY in PD models, but promising results have been
obtained in rodent PD model using direct infusion of
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NPY ligands [142] and in other neurodegenerative
diseases [145] which encourage further research on
this target.
The transcription factor EB (TFEB) has been found
to be a key player in regulating the autophagy-
lysosomal pathway [146] which is found to be
impaired in PD [147]. By overexpressing TFEB,
Decressac et al. (2013) reported neuroprotection as
well as rescue of a parkinsonian phenotype in a rat
model overexpressing SNCA in the SN and ventral
tegmental area [148]. These results point to TFEB
as another potential future target in the pursuit of
therapies for PD.
Optogenetics
Optogenetics is a rapidly emerging technology
using targeted expression of light-sensitive ion chan-
nels (opsins) or G-protein coupled receptors which
enables precise control of neural activity of trans-
fected specific cell populations. The opsins are
activated using light pulses with a wavelength spe-
cific for the used opsins [149]. The technology has
so far been used to decipher hitherto unknown neural
mechanisms and may prove to be a viable therapeu-
tic option in itself. The technology has been explored
in a wide number of fields, such as management of
pain [150], epilepsy [151], depression [152], cardiac
arrhythmias [153], retinal dystrophy [154] and PD.
The primary focus of optogenetic studies of PD has so
far been aimed at deconstructing the parkinsonian cir-
cuitry and mapping the effects of DBS. Nevertheless,
several recent publications show optogenetic stim-
ulation to improve motor behavior in parkinsonian
rodents. For instance, two studies show that high fre-
quency optogenetic stimulation of the STN or the 5th
layer of the neocortical M1 area improves locomotor
behavior in 6-OHDA-treated mice [155, 156]. This
suggests that optogenetic stimulation might be used
as a more selective alternative to electrical DBS, stim-
ulating selective STN populations as opposed to the
unspecific effects of electrical DBS. The two studies
also suggest the neocortex as a new possible target
for DBS. Consistent with these latter studies, Yoon
et al. found that optogenetic low frequency inhibi-
tion of glutamatergic cells in the STN using the light
sensitive Cl−-channel NpHR was both able to reduce
parkinsonian behavior [157] and to reduce L-DOPA-
induced dyskinesia in 6-OHDA treated rats [158].
Kravitz et al. (2010) [159] investigated the classic
concept of parkinsonian motor deficits being driven
by an imbalance between the “direct” and “indirect”
basal ganglial pathways. The authors overexpressed
channelrhodopsin-2 (ChR2) in either the D2- or D1-
expressing medium spiny projection neurons in the
striatum of mice. Bilateral excitation of the D2-
expressing neurons of the indirect pathway induced
a parkinsonian phenotype in the mice. On the other
hand, they completely rescued PD behavior in 6-
OHDA-treated mice by activating the D1-expressing
neurons of the direct pathway. Further research on
the subject by the same group showed that activation
of the two pathways induced changes in the firing
pattern of the SN pars reticulata (SNr) [160]. By acti-
vating the direct pathway, it was possible to detect
a reduction in the firing rate of a subset of nigral
neurons. By activating the indirect pathway, it was
possible to detect increased activity in one subset of
neurons as well as reduced activity in another sub-
set. The authors explain this modulation of firing rate
with the possibility of the inhibited nigral cells being
silenced to avoid executing multiple motor actions
simultaneously [160]. If this holds true in further
studies, it would be a theoretical possibility to tai-
lor optogenetic stimulation when needed, rather than
the continuous stimulation protocols presently used.
In a recent study Moon et al. (2017) NpHR was
expressed in the entopeduncular nucleus (EN) of
an AAV2--synuclein-induced hemiparkinsonian rat
model to monitor the effect of inhibition of the rat
equivalent of GPi on thalamic activity and ultimately
on motor behavior [161]. By inhibiting EN activity,
improved contralateral forelimb use in amphetamine-
induced rotations, cylinder test and stepping test was
seen.
Optogenetics is an evolving field and provides
crucial insights into neuronal circuitry and may in
time provide viable treatment options for PD. This
progress may be boosted by the recent development
of an inhibitory opsin capable of activation by tran-
scranial light [162]. Thus, optogenetic inhibition of
the STN or stimulation of the M1 motor cortex could
become a feasible alternative to DBS as this poten-
tially avoids the need for implantation of electrodes
or optic cables.
Chemogenetics
G-protein coupled receptors (GPCR) are found in
abundance all over the body and contributes to a great
number of physiological processes. Researchers have
succeeded in engineering GPCRs only responsive
to otherwise inert substances such as the clozap-
ine metabolite clozapine-N-oxide (CNO) [163–165].
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These receptors are known as designer receptors
exclusively activated by designer drugs (DREADDs)
and have been developed to initiate the activation of
several different G-proteins, including Gi, Gs, and
Gq [166]. By expressing DREADDs under a pro-
motor specific for the desired cell population, it is
possible to achieve pharmacological control over the
cells without inducing off-target effects. Chemoge-
netics, similarly to optogenetics, has been widely
used to probe neural circuits, but also carries the
potential to work as a therapy by itself. So far,
DREADDs have mainly seen use in other fields. In
one in vivo study, though, DREADDs were utilized
in a PD model. Pienaar et al. used an AAV-vector to
express an excitatory DREADD in cholinergic cells
in the rat pedunculopontine nucleus (PPN) [167].
The authors of this study utilized a novel rat model
treated with the irreversible ubiquitin-proteasome
inhibitor lactacystin, leading to disrupted breakdown
of SNCA resulting in a parkinsonian phenotype
[168]. After treatment, the transgenetic lactacystin-
treated rats [168] showed a marked improvement
in motor behavior, when treated with the otherwise
pharmacologically inert CNO, potentially suggesting
PPN as a future target for PD therapy using chemo-
genetics [167]. A standing concern regarding gene
therapy is the fact that the therapy is irreversible and,
in most cases, uncontrollable. Opto- and chemoge-
netics, in contrast, can be applied when necessary
and side effects may therefore be few.
Genome editing
Mutations in several genes have been asso-
ciated with both familial- and sporadic PD,
including parkin, LRRK2, SNCA, PINK1, DJ-1,
VPS35, DNAJC13, CHCHD2 [169]. Several of
these mutations potentially influence neuroplasticity,
immunomodulation, endosomal sorting, autophagy
and mitochondrial function linked to the develop-
ment of PD [170–177]. The recently developed
“clustered regularly interspaced short palindromic
repeats” technology (CRISPR) in conjunction with
the endonuclease CAS9 [178] are able to induce
double-stranded DNA-breaks and with that, the pos-
sibility of editing genes responsible for familial
parkinsonism is now a theoretical possibility [179].
Thus the technology could be employed in adults with
brain region-specific injections of vectors encoding
CRISPR-CAS9 constructs to correct gene mutations
responsible for focal disease activity [180]. It remains
to be seen what will be the time window in the
lifespan of individual patients for editing disease
genes in this manner. With CRISPR-CAS9 comes
also the possibility of altering the germ cell DNA and
thus sparing future generations from familial parkin-
sonism [181]. However, this approach is, as of yet,
not approved by any ethics committee.
CONCLUSION
Gene therapy offers a promising potential treat-
ment avenue for PD with the theoretical possibility
of targeting both non-disease and disease modify-
ing targets. While encouraging results have been
obtained in clinical trials using non-disease modify-
ing treatment, a disease modifying gene therapeutic
treatment remains to be identified as effective in slow-
ing or reversing PD disease progression. Prosavin and
AADC dopaminogenic therapies have been shown to
be both safe and successful at reducing the need for
medication in advanced PD patients. The same also
appears to be the case for overexpression of GAD
in the STN. These therapies should be further val-
idated in clinical studies and could potentially be
applied in conjunction with electrode implantation or
as an alternative to it in order to avoid DBS-induced
adverse effects such as speech impediments, pares-
thesia, cognitive impairment, and mood disturbances
[182].
As for disease modifying targets, research target-
ing GFL family members (GDNF, NRTN, ARTN,
PSPN) is still ongoing, with a planned clinical study
examining putaminal overexpression of GDNF. The
CDNF/MANF family might also be a viable alter-
native to the GFL family, as this family of growth
factors exerts its neuroprotective effect via a differ-
ent mechanism than the GFL family. The ongoing
NHP trial with CDNF vs GDNF will be most inter-
esting. The possibility of combining Nurr1 therapy
with a member of the GFL family might also be an
interesting approach. In the investigation of growth
factors for PD, researchers are challenged by the
validity of the PD animal models used. For instance,
6-OHDA and MPTP-treated animals phenotypically
display parkinsonistic symptoms, but the pathophys-
iology does not adequately mirror PD. This warrants
more accurate PD models and their implementation
in PD research such as the lactacystine model for PPN
and a more finely tuned SNCA model. By utilizing the
novel CRISPR-CAS9 technology it should be possi-
ble to engineer animals suffering mutations that result
in true PD rather than an artificially induced one.
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Another hurdle faced in exploring the use of growth
factors, is the high PD disease load of the subjects in
the trials. Thus, there must be dopaminergic neurons
left to save if the growth factors are to have any effect.
Future trials should attempt to investigate the effect of
GFL gene therapy in patients at earlier disease stages
before abandoning the target for potential therapy.
At a longer perspective, gene therapy with growth
factors could be relevant as an aggressive treatment
regime in patients with early verified PD, rather than
as a last-line of treatment.
Gene therapy with opto- and chemogenetics
could prove a viable alternative option for treating
symptoms of PD as they provide a more specific inter-
vention as compared to DBS or ablation. Genome
editing with the CRISPR-CAS9 technology might
be another future form of personalized gene therapy
for known mutations leading to PD. In conclusion,
while gene therapy has yet to deliver the true cure for
PD, there is increasing data supporting that this treat-
ment modality could become an important avenue for
future PD treatment.
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